Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

$NBIX (+1,61 %)

Neurocrine reports a very strong quarter with 39% revenue growth, driven by INGREZZA and the new product VYKAT XR. The full-year guidance has been raised, the pipeline is performing well, and the Soleno acquisition has been integrated.

🔹 Key Financial Figures for Q2 2026

• Revenue: $959 million (+39% YoY)
• INGREZZA Revenue: $716 million (+15% YoY)
• CRENESSITY Revenue: $184 million (+247% YoY)
• VYKAT XR: $54 million (as of acquisition date)
• GAAP EPS: $1.39
• Non-GAAP EPS: $2.85
• GAAP Net Income: $144 million
• Non-GAAP net income: $297 million

🔹 2026 Guidance (updated)

• INGREZZA: $2.825–2.875 billion (raised)
• R&D: slightly increased
• SG&A: significantly increased due to launch activities and the integration of Soleno
• Depreciation and amortization: $85–90 million for VYKAT-XR-IP

🔹 Strategic Highlights

• Soleno acquisition completed (USD 2.9 billion) → strengthens rare disease portfolio
• VYKAT XR shows strong clinical data for Prader-Willi syndrome
• CRENESSITY with positive 2-year data
• Pipeline: Phase 3 milestones in 2027 (osavampator, direclidine)
• Cash: $482 million after acquisition

🔹 Conclusion

Very strong growth, successful integration of the acquisition, robust pipeline, and an upwardly revised forecast. The company is showing clear momentum.

So why is the stock price falling?

The stock price is NOT falling because the numbers are bad. The numbers are strong. The price is falling for market psychology and structural reasons, not because of the results themselves.

Here’s the concise, clear explanation—based on the earnings report from your tab.

⭐ 1) Expectations were higher than the actual figures

39% revenue growth sounds incredibly good—but: The market had expected even more , especially after the Soleno acquisition and the strong momentum.

→ “Good numbers, but not good enough” often leads to a drop in the stock price.

⭐ 2) SG&A and R&D are rising sharply

The report makes it clear:

• SG&A: +154 million YoY
• R&D: +82 million YoY

These are massive cost increases. The market sees: Growth, yes, but at a high cost.

→ This is weighing on sentiment.

⭐ 3) Cash has fallen sharply

Cash balance:

• End of 2025: 2.543 billion USD
• Q2 2026: 482 million USD

That is a huge decline, mainly due to the Soleno acquisition.

The market doesn’t like companies that suddenly look “poor”—even if it made strategic sense.

⭐ 4) Integration of Soleno = Risk

The report emphasizes several times:

• high integration costs
• high amortization
• Uncertainty about how quickly VYKAT XR will scale

Biotech investors hate integration risks.

⭐ 5) Guidance was raised—but not enough

INGREZZA guidance was raised, yes. But the market wanted a big, aggressive increase after a quarter like that.

→ Expectations > Reality = pressure on the stock price.

⭐ 6) Classic “sell the news” effect

When a stock has performed strongly ahead of earnings, this often happens:

• good numbers → investors take profits
• Price falls despite good results

This is a typical pattern.

🎯 Quick summary

The price falls because:

• Expectations were higher
• Costs are rising sharply
• Cash has fallen sharply
• The integration of Soleno risks is leading to
• Investors are taking profits

*researched using AI